Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,"GPCRs, Class A Rhodopsin-like WP455",3.321620959061578e-06,7.5499920898592,95.24358549708336,"['P2RY12', 'CX3CR1', 'P2RY13', 'CHRM3', 'CYSLTR1', 'HRH1', 'GPR34', 'HRH2', 'GPR65', 'ADRB2', 'OPRM1']",0.0014050456656830475,0,0,11
2,Complement system WP2806,1.2136896652002118e-05,6.339069767441861,71.75358161327878,"['C5', 'FCGR3A', 'SELPLG', 'CD93', 'PROS1', 'ITGAX', 'SPP1', 'F13A1', 'VSIG4', 'CD55', 'TLR2']",0.002566953641898448,0,0,11
3,Lung fibrosis WP3624,4.716063806510934e-05,8.202125147579693,81.70916842721127,"['CEBPB', 'SERPINA1', 'FAM13A', 'SPP1', 'HMOX1', 'ATP11A', 'IGF1', 'FGF2']",0.006649649967180417,0,0,8
4,Vitamin D Receptor Pathway WP2877,0.00013356203974173724,3.904513888888889,34.83195158865503,"['CEBPA', 'TNFAIP3', 'ADRB2', 'HIF1A', 'CRACR2A', 'DUSP10', 'BCL6', 'SPP1', 'CD9', 'PRKCQ', 'S100A9', 'S100A8', 'PPARD']",0.014124185702688714,0,0,13
5,Monoamine GPCRs WP58,0.0002507870909755993,28.558292282430212,236.77412317179235,"['CHRM3', 'HRH1', 'HRH2', 'ADRB2']",0.021216587896535702,0,0,4
6,Nuclear Receptors Meta-Pathway WP2882,0.0006640278891530066,2.3940067035539476,17.517393311028265,"['CPT1A', 'SERPINA1', 'ABCB4', 'STAT3', 'TNFAIP3', 'NRG1', 'SLC2A5', 'SLC5A3', 'SLC6A6', 'SLC5A9', 'SEC14L1', 'SCD', 'BHLHE40', 'PDE4B', 'HMOX1', 'PLTP', 'CPEB4', 'PPARD', 'HSPA1A', 'FKBP5', 'FTL']",0.04448593882737838,0,0,21
7,Endochondral Ossification with Skeletal Dysplasias WP4808,0.0008625235012132093,4.779063360881542,33.719389616596196,"['HDAC4', 'SPP1', 'ENPP1', 'PLAT', 'IGF1', 'FGF2', 'SLC38A2', 'VEGFA']",0.04448593882737838,0,0,8
8,Endochondral Ossification WP474,0.0008625235012132093,4.779063360881542,33.719389616596196,"['HDAC4', 'SPP1', 'ENPP1', 'PLAT', 'IGF1', 'FGF2', 'SLC38A2', 'VEGFA']",0.04448593882737838,0,0,8
9,Cardiac Progenitor Differentiation WP2406,0.0010042964207383157,8.93297697368421,61.66852123201612,"['NOTCH1', 'NRG1', 'ROR2', 'IGF1', 'FGF2']",0.04448593882737838,0,0,5
10,Development and heterogeneity of the ILC family WP3893,0.0010516770408363684,14.275862068965518,97.89485695798783,"['NFIL3', 'IL15', 'ZBTB16', 'ID2']",0.04448593882737838,0,0,4
11,PTF1A related regulatory pathway WP4147,0.0025685886837305784,21.38360655737705,127.54035475038974,"['NOTCH1', 'PROX1', 'RBPJ']",0.0987739102925486,0,0,3
12,HIF1A and PPARG regulation of glycolysis WP2456,0.004886402008543244,14.254098360655737,75.85031980705634,"['LDHA', 'TPI1', 'HIF1A']",0.16599972557226397,0,0,3
13,"GPCRs, Other WP117",0.0065240035374715104,5.101033834586466,25.669764496922557,"['CHRM3', 'ADGRE2', 'P2RY13', 'ADRB2', 'ADGRL2']",0.16599972557226397,0,0,5
14,IL-4 signaling pathway WP395,0.007237007288517071,3.1816345270890727,15.680836945241326,"['STAT5A', 'CEBPA', 'CEBPB', 'HRH1', 'IL4R', 'NFIL3', 'STAT3', 'JAK3']",0.16599972557226397,0,0,8
15,NRF2 pathway WP2884,0.007627231310384804,2.7050283175318377,13.189800223739113,"['SLC6A6', 'SLC5A9', 'SERPINA1', 'HMOX1', 'NRG1', 'SLC2A5', 'SLC5A3', 'FTL', 'PPARD', 'HSPA1A']",0.16599972557226397,0,0,10
16,TYROBP causal network in microglia WP3945,0.008088673020132987,2.86523178807947,13.802654126710305,"['STAT5A', 'ADAP2', 'DPYD', 'ITGAX', 'SPP1', 'HCLS1', 'TCIRG1', 'TNFRSF1B', 'GAL3ST4']",0.16599972557226397,0,0,9
17,Differentiation of white and brown adipocyte WP2895,0.008135208634290184,10.689344262295082,51.43235598965363,"['PLAC8', 'CEBPA', 'CEBPB']",0.16599972557226397,0,0,3
18,Genes targeted by miRNAs in adipocytes WP1992,0.008135208634290184,10.689344262295082,51.43235598965363,"['HDAC4', 'IGF1', 'KCNJ2']",0.16599972557226397,0,0,3
19,"GPCRs, Class B Secretin-like WP334",0.008135208634290184,10.689344262295082,51.43235598965363,"['ADGRE2', 'CALCR', 'ADGRL2']",0.16599972557226397,0,0,3
20,Differentiation Pathway WP2848,0.008241121127701048,6.341178617040686,30.428899465707303,"['NOTCH1', 'IGF1', 'FGF2', 'VEGFA']",0.16599972557226397,0,0,4
21,Eicosanoid metabolism via lipooxygenases (LOX) WP4721,0.008241121127701048,6.341178617040686,30.428899465707303,"['CYSLTR1', 'LTC4S', 'ALOX15B', 'PPARD']",0.16599972557226397,0,0,4
22,Development of pulmonary dendritic cells and macrophage subsets WP3892,0.012385341488682363,8.550491803278689,37.547275680304516,"['BATF3', 'ID2', 'STAT3']",0.2381363386233018,0,0,3
23,Oxysterols derived from cholesterol WP4545,0.014163641171729704,5.187042842215256,22.081641190744875,"['CH25H', 'DBP', 'ACOT7', 'ACOT11']",0.26048783546268106,0,0,4
24,Cell Differentiation - Index expanded WP2023,0.017680615091151583,7.1245901639344265,28.749762023184573,"['ID2', 'STAT3', 'EZH2']",0.28077640129605547,0,0,3
25,Cori Cycle WP1946,0.017680615091151583,7.1245901639344265,28.749762023184573,"['LDHA', 'TPI1', 'PGAM1']",0.28077640129605547,0,0,3
26,NOTCH1 regulation of endothelial cell calcification WP3413,0.017680615091151583,7.1245901639344265,28.749762023184573,"['NOTCH1', 'PLAT', 'VEGFA']",0.28077640129605547,0,0,3
27,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) WP2817,0.01792189795506737,4.75424192665572,19.120286722791363,"['CEBPA', 'PTPN1', 'CEBPB', 'TNFRSF11A']",0.28077640129605547,0,0,4
28,PPAR signaling pathway WP3942,0.01913841501572575,3.1744462749405087,12.558292649632586,"['CPT1A', 'ACSL1', 'SCD', 'OLR1', 'PLTP', 'PPARD']",0.28912676970185686,0,0,6
29,Regulatory circuits of the STAT3 signaling pathway WP4538,0.02101044985096542,2.7793362669600294,10.735840456472085,"['PTPRT', 'IFNAR2', 'STAT3', 'IL21R', 'CSF2RB', 'JAK3', 'CSF2RA']",0.30646276851580595,0,0,7
30,MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma WP3593,0.02374994119024928,14.23240589198036,53.23169190512447,"['HIF1A', 'VEGFA']",0.3103984627115651,0,0,2
31,Spinal Cord Injury WP2431,0.02392252451634689,2.487100251527129,9.284183118533589,"['ZFP36', 'C5', 'GAP43', 'FCGR2A', 'TNFSF13', 'LILRB3', 'TNFSF13B', 'RHOB']",0.3103984627115651,0,0,8
32,Development of ureteric collection system WP5053,0.02404236577258525,6.106088992974239,22.763119749181357,"['ROBO2', 'GRIP1', 'SALL1']",0.3103984627115651,0,0,3
33,Hematopoietic Stem Cell Differentiation WP2849,0.025236250889676473,3.3979479949874687,12.502660590009997,"['STAT5A', 'NOTCH1', 'PIM1', 'RHOH', 'RUNX1']",0.3103984627115651,0,0,5
34,Adipogenesis WP236,0.025683087931216975,2.299491485335856,8.42055974862625,"['STAT5A', 'CEBPA', 'CEBPB', 'WNT5B', 'SCD', 'STAT3', 'IGF1', 'HIF1A', 'PPARD']",0.3103984627115651,0,0,9
35,Toll-like Receptor Signaling Pathway WP75,0.025683087931216975,2.299491485335856,8.42055974862625,"['IFNAR2', 'TICAM2', 'SPP1', 'LY96', 'MAP3K8', 'TLR5', 'IKBKE', 'MAP2K6', 'TLR2']",0.3103984627115651,0,0,9
36,Complement and Coagulation Cascades WP558,0.027149194513645586,4.0741262022050195,14.692960925498799,"['SERPINA1', 'PROS1', 'PLAT', 'CD55']",0.31900303553533566,0,0,4
37,7-oxo-C and 7beta-HC pathways WP5064,0.031473020292108245,5.342213114754099,18.47670969081844,"['DBP', 'ACOT7', 'ACOT11']",0.35981317793410234,0,0,3
38,Glycolysis and Gluconeogenesis WP534,0.033858380776544864,3.1017591533180777,10.501218780561668,"['LDHA', 'TPI1', 'PGAM1', 'ALDOC', 'SLC2A5']",0.3756168647300988,0,0,5
39,GDNF/RET signaling axis WP4830,0.03787087713884374,9.487179487179487,31.056973434208412,"['ROBO2', 'SALL1']",0.3756168647300988,0,0,2
40,Inflammatory Response Pathway WP453,0.03787087713884374,9.487179487179487,31.056973434208412,"['IL4R', 'TNFRSF1B']",0.3756168647300988,0,0,2
41,Mammary gland development pathway - Involution (Stage 4 of 4) WP2815,0.03787087713884374,9.487179487179487,31.056973434208412,"['STAT3', 'CHI3L1']",0.3756168647300988,0,0,2
42,Proximal tubule transport WP4917,0.03875251310556976,3.564039408866995,11.585122768134003,"['SLC7A8', 'CA2', 'SLC4A2', 'ATP6V1F']",0.3756168647300988,0,0,4
43,Deregulation of Rab and Rab Effector Genes in Bladder Cancer WP2291,0.039959240928733916,4.748087431693989,15.288344505768347,"['RPH3AL', 'RAB27A', 'UNC13D']",0.3756168647300988,0,0,3
44,Extracellular vesicles in the crosstalk of cardiac cells WP4300,0.039959240928733916,4.748087431693989,15.288344505768347,"['STAT3', 'SPP1', 'IGF1']",0.3756168647300988,0,0,3
45,Genes controlling nephrogenesis WP4823,0.039959240928733916,4.748087431693989,15.288344505768347,"['ROBO2', 'CXCL12', 'VEGFA']",0.3756168647300988,0,0,3
46,MECP2 and Associated Rett Syndrome WP3584,0.04820010045111355,2.2719021902190217,6.889302965244816,"['RBFOX1', 'BCL6', 'YBX1', 'IGF1', 'FGF2', 'FKBP5', 'EZH2']",0.4357891966533585,0,0,7
47,Ectoderm Differentiation WP2858,0.05177571211510098,1.9066887783305693,5.645389186833678,"['SDCBP', 'PTPRB', 'ZBTB16', 'PIM1', 'HMGB2', 'SPRY2', 'SORCS1', 'ROR2', 'LDB2', 'PPARD']",0.4357891966533585,0,0,10
48,Cells and molecules involved in local acute inflammatory response  WP4493,0.05436314473234019,7.114566284779051,20.718106796954213,"['C5', 'SELPLG']",0.4357891966533585,0,0,2
49,Farnesoid X receptor pathway WP2879,0.05436314473234019,7.114566284779051,20.718106796954213,"['ABCB4', 'FKBP5']",0.4357891966533585,0,0,2
50,FOXP3 in COVID-19 WP5063,0.05436314473234019,7.114566284779051,20.718106796954213,"['STAT5A', 'STAT3']",0.4357891966533585,0,0,2
51,Macrophage markers WP4146,0.05436314473234019,7.114566284779051,20.718106796954213,"['CD163', 'CD83']",0.4357891966533585,0,0,2
52,"Metabolic pathway of LDL, HDL and TG, including diseases WP4522",0.05436314473234019,7.114566284779051,20.718106796954213,"['LIPC', 'LIPG']",0.4357891966533585,0,0,2
53,Heart Development WP1591,0.059982457136599485,3.8839046199701937,10.928154626878198,"['NOTCH1', 'BHLHE40', 'VEGFA']",0.4357891966533585,0,0,3
54,IL-9 signaling pathway WP22,0.059982457136599485,3.8839046199701937,10.928154626878198,"['STAT5A', 'STAT3', 'JAK3']",0.4357891966533585,0,0,3
55,"COVID-19, thrombosis and anticoagulation WP4927",0.0658358754720593,inf,inf,['F13A1'],0.4357891966533585,0,0,1
56,SCFA and skeletal muscle substrate metabolism WP4030,0.0658358754720593,inf,inf,['PPARD'],0.4357891966533585,0,0,1
57,Regulation of toll-like receptor signaling pathway WP1449,0.06682690505054742,1.8093078909251212,4.895353007275725,"['IFNAR2', 'TICAM2', 'SPP1', 'LY96', 'TNFAIP3', 'MAP3K8', 'TLR5', 'IKBKE', 'MAP2K6', 'TLR2']",0.4357891966533585,0,0,10
58,Type I interferon induction and signaling during SARS-CoV-2 infection WP4868,0.06919626258733252,2.8499178981937603,7.611584737815318,"['IFNAR2', 'OAS1', 'IKBKE', 'TLR2']",0.4357891966533585,0,0,4
59,Angiogenesis WP1539,0.07143717333567955,3.5598360655737706,9.394182787584366,"['HIF1A', 'FGF2', 'VEGFA']",0.4357891966533585,0,0,3
60,Gastric Cancer Network 2 WP2363,0.07143717333567955,3.5598360655737706,9.394182787584366,"['PLAC8', 'RNF144B', 'ATAD2']",0.4357891966533585,0,0,3
61,Hereditary leiomyomatosis and renal cell carcinoma pathway WP4206,0.07143717333567955,3.5598360655737706,9.394182787584366,"['LDHA', 'HIF1A', 'VEGFA']",0.4357891966533585,0,0,3
62,Immune response to tuberculosis WP4197,0.07143717333567955,3.5598360655737706,9.394182787584366,"['IFNAR2', 'OAS1', 'PTPN2']",0.4357891966533585,0,0,3
63,White fat cell differentiation WP4149,0.07143717333567955,3.5598360655737706,9.394182787584366,"['STAT5A', 'CEBPA', 'CEBPB']",0.4357891966533585,0,0,3
64,Amplification and Expansion of Oncogenic Pathways as Metastatic Traits WP3678,0.07285434508232191,5.690998363338789,14.906392767327118,"['NOTCH1', 'VEGFA']",0.4357891966533585,0,0,2
65,Complement Activation WP545,0.07285434508232191,5.690998363338789,14.906392767327118,"['C5', 'CD55']",0.4357891966533585,0,0,2
66,Dual hijack model of Vif in HIV infection WP3300,0.07285434508232191,5.690998363338789,14.906392767327118,"['ELOC', 'RUNX1']",0.4357891966533585,0,0,2
67,FGF23 signaling in hypophosphatemic rickets and related disorders WP4790,0.07285434508232191,5.690998363338789,14.906392767327118,"['SPP1', 'ENPP1']",0.4357891966533585,0,0,2
68,Platelet-mediated interactions with vascular and circulating cells WP4462,0.07285434508232191,5.690998363338789,14.906392767327118,"['SELPLG', 'TLR2']",0.4357891966533585,0,0,2
69,Transcriptional cascade regulating adipogenesis WP4211,0.07285434508232191,5.690998363338789,14.906392767327118,"['CEBPA', 'CEBPB']",0.4357891966533585,0,0,2
70,Cardiac Hypertrophic Response WP2795,0.07285727529102415,2.1946521353440627,5.748348936195224,"['HDAC4', 'NRG1', 'IGF1', 'FGF2', 'IKBKE', 'MAP2K6']",0.4357891966533585,0,0,6
71,Pathways in clear cell renal cell carcinoma WP4018,0.07314665002928714,2.0388967468175387,5.332304129029974,"['LDHA', 'TPI1', 'STAT3', 'ALDOC', 'HIF1A', 'KCNJ2', 'VEGFA']",0.4357891966533585,0,0,7
72,Neural Crest Differentiation WP2064,0.07702932236458901,2.37609649122807,6.091287590312298,"['HDAC4', 'NOTCH1', 'RBPJ', 'FGF2', 'RHOB']",0.45254726889196045,0,0,5
73,Toll-like Receptor Signaling related to MyD88 WP3858,0.07827871141131673,2.71389475330362,6.9135915147958045,"['TICAM2', 'TLR5', 'IKBKE', 'TLR2']",0.4535876017395476,0,0,4
74,Statin inhibition of cholesterol production WP430,0.08378686357843605,3.2856242118537202,8.146636376429585,"['LIPC', 'APOC1', 'PLTP']",0.4663400433378744,0,0,3
75,STING pathway in Kawasaki-like disease and COVID-19 WP4961,0.08378686357843605,3.2856242118537202,8.146636376429585,"['GSDMD', 'FCGR2A', 'IKBKE']",0.4663400433378744,0,0,3
76,Type I collagen synthesis in the context of Osteogenesis imperfecta WP4786,0.08378686357843605,3.2856242118537202,8.146636376429585,"['P3H2', 'P3H1', 'TNFRSF11A']",0.4663400433378744,0,0,3
77,Epithelial to mesenchymal transition in colorectal cancer WP4239,0.0878587103039115,1.8418555051986136,4.479439223563444,"['NOTCH1', 'WNT5B', 'ID2', 'PROX1', 'RBPJ', 'HIF1A', 'MAP2K6', 'EZH2']",0.4755987027185646,0,0,8
78,Fatty acid beta-oxidation WP143,0.08792280221222891,2.5902373488580386,6.29763395683883,"['CPT1A', 'LIPC', 'TPI1', 'ACSL1']",0.4755987027185646,0,0,4
79,IL-10 Anti-inflammatory Signaling Pathway  WP4495,0.09301070162404598,4.741953082378615,11.262331668777023,"['STAT3', 'HMOX1']",0.4755987027185646,0,0,2
80,Nuclear Receptors in Lipid Metabolism and Toxicity WP299,0.09301070162404598,4.741953082378615,11.262331668777023,"['ABCB4', 'PPARD']",0.4755987027185646,0,0,2
81,Osteoclast Signaling WP12,0.09301070162404598,4.741953082378615,11.262331668777023,"['SPP1', 'TNFRSF11A']",0.4755987027185646,0,0,2
82,Glucocorticoid Receptor Pathway WP2880,0.09308132755339292,2.227076480263158,5.287706882929622,"['SEC14L1', 'BHLHE40', 'PDE4B', 'TNFAIP3', 'CPEB4']",0.4755987027185646,0,0,5
83,Oncostatin M Signaling Pathway WP2374,0.0933207856398129,2.037185220051777,4.831617474164846,"['CEBPB', 'PXN', 'STAT3', 'JAK3', 'HIF1A', 'VEGFA']",0.4755987027185646,0,0,6
84,MicroRNAs in cardiomyocyte hypertrophy WP1544,0.09770685449550198,1.884145961765988,4.382115709659488,"['HDAC4', 'STAT3', 'NRG1', 'IGF1', 'FGF2', 'IKBKE', 'MAP2K6']",0.49202380299520637,0,0,7
85,IL-18 signaling pathway WP4754,0.09977286470115203,1.5167197855010877,3.4958252927081954,"['SPON1', 'CPT1A', 'CEBPB', 'NRN1', 'CD83', 'TICAM2', 'HSPB8', 'TNFAIP2', 'TNFAIP3', 'VEGFA', 'NFKBIZ', 'SPP1', 'HMOX1', 'CDK5R2']",0.49651672668926244,0,0,14
86,Arrhythmogenic Right Ventricular Cardiomyopathy WP2118,0.11070172382086788,2.0955882352941178,4.612213398563236,"['RYR2', 'LAMA2', 'CACNA2D3', 'CTNNA3', 'CACNA1C']",0.5383079285858039,0,0,5
87,Computational Model of Aerobic Glycolysis WP4629,0.11453360182676678,4.06406359597849,8.806366708650788,"['LDHA', 'TPI1']",0.5383079285858039,0,0,2
88,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma WP4337,0.11453360182676678,4.06406359597849,8.806366708650788,"['STAT3', 'JAK3']",0.5383079285858039,0,0,2
89,Peptide GPCRs WP24,0.11453360182676678,4.06406359597849,8.806366708650788,"['CX3CR1', 'OPRM1']",0.5383079285858039,0,0,2
90,Pyrimidine metabolism and related diseases WP4225,0.11453360182676678,4.06406359597849,8.806366708650788,"['DPYD', 'TYMP']",0.5383079285858039,0,0,2
91,Allograft Rejection WP2328,0.12007413943486843,2.035479323308271,4.314495398834176,"['C5', 'CXCL12', 'LRRK2', 'CD55', 'VEGFA']",0.5386655846494101,0,0,5
92,Neovascularisation processes WP4331,0.12561908107181113,2.6686475409836063,5.536112304983543,"['NOTCH1', 'CXCL12', 'HIF1A']",0.5386655846494101,0,0,3
93,Photodynamic therapy-induced unfolded protein response WP3613,0.12561908107181113,2.6686475409836063,5.536112304983543,"['DNAJC3', 'XBP1', 'HSPA5']",0.5386655846494101,0,0,3
94,Blood Clotting Cascade WP272,0.1273441098461962,14.21078431372549,29.286470076527607,['PLAT'],0.5386655846494101,0,0,1
95,Catalytic cycle of mammalian Flavin-containing MonoOxygenases (FMOs) WP688,0.1273441098461962,14.21078431372549,29.286470076527607,['FMO4'],0.5386655846494101,0,0,1
96,Gene regulatory network modelling somitogenesis  WP2854,0.1273441098461962,14.21078431372549,29.286470076527607,['NOTCH1'],0.5386655846494101,0,0,1
97,Hfe effect on hepcidin production WP3924,0.1273441098461962,14.21078431372549,29.286470076527607,['HAMP'],0.5386655846494101,0,0,1
98,SARS-CoV-2 altering angiogenesis via NRP1 WP5065,0.1273441098461962,14.21078431372549,29.286470076527607,['VEGFA'],0.5386655846494101,0,0,1
99,Secretion of Hydrochloric Acid in Parietal Cells WP2597,0.1273441098461962,14.21078431372549,29.286470076527607,['HRH2'],0.5386655846494101,0,0,1
100,Somitogenesis in the context of spondylocostal dysostosis WP4785,0.1273441098461962,14.21078431372549,29.286470076527607,['NOTCH1'],0.5386655846494101,0,0,1
101,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.13158121002768036,1.439161191914582,2.9188075010468064,"['IFNAR2', 'IL4R', 'LAMA2', 'IGF1', 'HIF1A', 'FGF2', 'EPOR', 'VEGFA', 'GNG10', 'GNG3', 'PIK3IP1', 'SPP1', 'ITGAX', 'JAK3']",0.5420109833596651,0,0,14
102,Autosomal recessive Osteopetrosis pathways WP4788,0.13715642576209602,3.555646481178396,7.063765384736619,"['TNFRSF11A', 'TCIRG1']",0.5420109833596651,0,0,2
103,Biomarkers for pyrimidine metabolism disorders WP4584,0.13715642576209602,3.555646481178396,7.063765384736619,"['DPYD', 'TYMP']",0.5420109833596651,0,0,2
104,Glycolysis in senescence WP5049,0.13715642576209602,3.555646481178396,7.063765384736619,"['LDHA', 'ALDOC']",0.5420109833596651,0,0,2
105,Iron metabolism in placenta WP2007,0.13715642576209602,3.555646481178396,7.063765384736619,"['STEAP3', 'HAMP']",0.5420109833596651,0,0,2
106,PPAR-alpha pathway WP2878,0.13715642576209602,3.555646481178396,7.063765384736619,"['CPT1A', 'PLTP']",0.5420109833596651,0,0,2
107,Urea cycle and metabolism of amino groups WP497,0.13715642576209602,3.555646481178396,7.063765384736619,"['ARG2', 'OAT']",0.5420109833596651,0,0,2
108,Notch Signaling Pathway Netpath WP61,0.1398806020924569,1.9250088904694167,3.7864271574608965,"['NOTCH1', 'STAT3', 'RBPJ', 'HIF1A', 'SAP30']",0.5420109833596651,0,0,5
109,EPO Receptor Signaling WP581,0.14094848267036209,2.5113789778206366,4.9206975896384915,"['STAT5A', 'STAT3', 'EPOR']",0.5420109833596651,0,0,3
110,IL-7 signaling pathway WP205,0.14094848267036209,2.5113789778206366,4.9206975896384915,"['STAT5A', 'STAT3', 'JAK3']",0.5420109833596651,0,0,3
111,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706,0.147290154625163,1.6067046909556513,3.0774031098520664,"['RYR2', 'SNAP25', 'CPT1A', 'CEBPB', 'BHLHE40', 'YBX1', 'HIF1A', 'VEGFA']",0.5612949135715671,0,0,8
112,Parkin-Ubiquitin Proteasomal System pathway WP2359,0.15152828772045374,1.7447466630803887,3.292307211994103,"['HSPA5', 'TUBB3', 'HSPA6', 'CASP1', 'HSPA1B', 'HSPA1A']",0.5722898723727851,0,0,6
113,The influence of laminopathies on Wnt signaling WP4844,0.15686287425804873,2.371584699453552,4.3930838150819636,"['CEBPA', 'CEBPB', 'SPP1']",0.575859433989659,0,0,3
114,Unfolded protein response WP4925,0.15686287425804873,2.371584699453552,4.3930838150819636,"['XBP1', 'HSPA5', 'TXNIP']",0.575859433989659,0,0,3
115,IL1 and megakaryocytes in obesity WP2865,0.16064163879616963,3.16021094744499,5.7786961352409305,"['S100A9', 'TLR2']",0.575859433989659,0,0,2
116,Interactions between immune cells and microRNAs in tumor microenvironment WP4559,0.16064163879616963,3.16021094744499,5.7786961352409305,"['IL4R', 'STAT3']",0.575859433989659,0,0,2
117,Omega-9 FA synthesis WP4724,0.16064163879616963,3.16021094744499,5.7786961352409305,"['ACSL1', 'SCD']",0.575859433989659,0,0,2
118,Phytochemical activity on NRF2 transcriptional activation WP3,0.16064163879616963,3.16021094744499,5.7786961352409305,"['CEBPB', 'HMOX1']",0.575859433989659,0,0,2
119,Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways) WP4718,0.16930820729981177,1.9634222297718136,3.487105643998371,"['CH25H', 'ACSL1', 'SCD', 'CYP51A1']",0.5922276953833422,0,0,4
120,The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies WP4879,0.16930820729981177,1.9634222297718136,3.487105643998371,"['CEBPA', 'CEBPB', 'NOTCH1', 'SPP1']",0.5922276953833422,0,0,4
121,3q29 copy number variation syndrome WP4906,0.17202532951932764,1.780016447368421,3.133031065323564,"['STAT5A', 'PXN', 'HIF1A', 'HAMP', 'PIGX']",0.5922276953833422,0,0,5
122,Ferroptosis WP4313,0.1826010338310328,1.8977558839627806,3.2270421224965773,"['STEAP3', 'ACSL1', 'HMOX1', 'FTL']",0.5922276953833422,0,0,4
123,Canonical and non-canonical Notch signaling WP3845,0.18477812734275942,2.843862520458265,4.802144788350537,"['NOTCH1', 'RBPJ']",0.5922276953833422,0,0,2
124,Eicosanoid Synthesis WP167,0.18477812734275942,2.843862520458265,4.802144788350537,"['LTC4S', 'ALOX15B']",0.5922276953833422,0,0,2
125,Imatinib and Chronic Myeloid Leukemia WP3640,0.18477812734275942,2.843862520458265,4.802144788350537,"['NOP2', 'PIM1']",0.5922276953833422,0,0,2
126,Mitochondrial LC-Fatty Acid Beta-Oxidation WP368,0.18477812734275942,2.843862520458265,4.802144788350537,"['CPT1A', 'ACSL1']",0.5922276953833422,0,0,2
127,"Oligodendrocyte specification and differentiation, leading to myelin components for CNS WP4304",0.18477812734275942,2.843862520458265,4.802144788350537,"['IGF1', 'FGF2']",0.5922276953833422,0,0,2
128,Wnt/beta-catenin signaling pathway in leukemia WP3658,0.18477812734275942,2.843862520458265,4.802144788350537,"['ZBTB16', 'PPARD']",0.5922276953833422,0,0,2
129,Biogenic Amine Synthesis WP550,0.184808642530972,7.104575163398692,11.995608775928961,['GAD2'],0.5922276953833422,0,0,1
130,Dopaminergic Neurogenesis WP2855,0.184808642530972,7.104575163398692,11.995608775928961,['STAT3'],0.5922276953833422,0,0,1
131,EV release from cardiac cells and their functional effects WP3297,0.184808642530972,7.104575163398692,11.995608775928961,['CXCL12'],0.5922276953833422,0,0,1
132,Folate-Alcohol and Cancer Pathway Hypotheses WP1589,0.184808642530972,7.104575163398692,11.995608775928961,['CEBPB'],0.5922276953833422,0,0,1
133,Photodynamic therapy-induced HIF-1 survival signaling WP3614,0.19018841610710774,2.133934426229508,3.5417763981547252,"['LDHA', 'HIF1A', 'VEGFA']",0.6048849625060645,0,0,3
134,GABA receptor Signaling WP4159,0.20747301267252016,2.0320843091334893,3.195968740116045,"['GAD2', 'GABRG3', 'GABRG1']",0.6417914122611587,0,0,3
135,Type 2 papillary renal cell carcinoma WP4241,0.20747301267252016,2.0320843091334893,3.195968740116045,"['ELOC', 'HIF1A', 'VEGFA']",0.6417914122611587,0,0,3
136,Gastric Cancer Network 1 WP2361,0.20937875861002342,2.5850319892873084,4.0419829673917675,"['NOTCH1', 'ECT2']",0.6417914122611587,0,0,2
137,Simplified Depiction of MYD88 Distinct Input-Output Pathway WP3877,0.20937875861002342,2.5850319892873084,4.0419829673917675,"['TLR5', 'TLR2']",0.6417914122611587,0,0,2
138,Transcription factor regulation in adipogenesis WP3599,0.20937875861002342,2.5850319892873084,4.0419829673917675,"['CEBPA', 'CEBPB']",0.6417914122611587,0,0,2
139,Endoplasmic reticulum stress response in coronavirus infection WP4861,0.22433369149780666,1.724635517738966,2.5776758437630516,"['PPP1R14B', 'XBP1', 'HSPA5', 'PPP1R3B']",0.655817955540088,0,0,4
140,Circadian rhythm related genes WP3594,0.2249147525487934,1.357182342256969,2.024961962874925,"['CPT1A', 'PER3', 'DBP', 'NFIL3', 'KCNH7', 'ID2', 'BHLHE40', 'PROX1', 'TNFRSF11A', 'EZH2']",0.655817955540088,0,0,10
141,Fibrin Complement Receptor 3 Signaling Pathway WP4136,0.22509041961024404,1.9394932935916542,2.892275372086137,"['TICAM2', 'LY96', 'PLAT']",0.655817955540088,0,0,3
142,PI3K-Akt signaling pathway WP4172,0.22720804795939414,1.2962121212121211,1.9208427049732437,"['IFNAR2', 'IL4R', 'LAMA2', 'IGF1', 'FGF2', 'EPOR', 'VEGFA', 'GNG10', 'GNG3', 'SPP1', 'PIK3AP1', 'JAK3', 'TLR2']",0.655817955540088,0,0,13
143,Interactome of polycomb repressive complex 2 (PRC2)  WP2916,0.23427814626173327,2.369339879978178,3.438495521689114,"['ELL', 'EZH2']",0.655817955540088,0,0,2
144,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement WP4560,0.23427814626173327,2.369339879978178,3.438495521689114,"['PXN', 'PRKCQ']",0.655817955540088,0,0,2
145,Pre-implantation embryo WP3527,0.23427814626173327,2.369339879978178,3.438495521689114,"['ZFP36', 'BATF3']",0.655817955540088,0,0,2
146,Cholesterol Biosynthesis with Skeletal Dysplasias WP4804,0.23849489518081365,4.735838779956427,6.788386223282573,['CYP51A1'],0.655817955540088,0,0,1
147,Liver X receptor pathway WP2874,0.23849489518081365,4.735838779956427,6.788386223282573,['SCD'],0.655817955540088,0,0,1
148,LncRNA-mediated mechanisms of therapeutic resistance WP3672,0.23849489518081365,4.735838779956427,6.788386223282573,['HIF1A'],0.655817955540088,0,0,1
149,miR-517 relationship with ARCN1 and USP1 WP3596,0.23849489518081365,4.735838779956427,6.788386223282573,['ID2'],0.655817955540088,0,0,1
150,Robo4 and VEGF Signaling Pathways Crosstalk WP3943,0.23849489518081365,4.735838779956427,6.788386223282573,['VEGFA'],0.655817955540088,0,0,1
151,Role of Osx and miRNAs in tooth development WP3971,0.23849489518081365,4.735838779956427,6.788386223282573,['NOTCH1'],0.655817955540088,0,0,1
152,Sulfation Biotransformation Reaction WP692,0.23849489518081365,4.735838779956427,6.788386223282573,['SULT4A1'],0.655817955540088,0,0,1
153,TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer WP2868,0.23849489518081365,4.735838779956427,6.788386223282573,['STAT3'],0.655817955540088,0,0,1
154,Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864,0.23876114693421643,1.673717762967256,2.3972519127224077,"['BEX3', 'HSPA5', 'NRG1', 'YBX3']",0.655817955540088,0,0,4
155,Thyroid hormones production and their peripheral downstream signaling effects WP4746,0.2560364122277258,1.51368281075028,2.062295362630958,"['NHSL1', 'NOTCH1', 'TBC1D4', 'PRKCQ', 'MGLL']",0.6987316282085677,0,0,5
156,Acute viral myocarditis WP4298,0.26880153358435804,1.4819764254385965,1.9469939003711858,"['LAMA2', 'STAT3', 'CASP1', 'TLR5', 'CD55']",0.7224812603522411,0,0,5
157,TNF-alpha signaling pathway WP231,0.2780168850998166,1.3995732843600617,1.7915565737609946,"['TNFAIP3', 'MAP3K8', 'PYGL', 'KSR2', 'TNFRSF1B', 'MAP2K6']",0.7224812603522411,0,0,6
158,Prader-Willi and Angelman Syndrome WP3998,0.27936356416726604,1.7061639344262296,2.175770625169485,"['PCSK1', 'GABRG3', 'GABRG1']",0.7224812603522411,0,0,3
159,Osteoblast differentiation WP4787,0.2817019485915056,1.4515641783029,1.8389949123429068,"['NOTCH1', 'WNT5B', 'PRKCQ', 'RBPJ', 'FGF2']",0.7224812603522411,0,0,5
160,Synaptic Vesicle Pathway WP2267,0.28317282079606576,1.537478365064572,1.9398332145552408,"['SNAP25', 'UNC13C', 'CACNA1A', 'SYN3']",0.7224812603522411,0,0,4
161,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma WP4553,0.28440828311405736,2.0303951367781155,2.5529060699427757,"['BCL6', 'EZH2']",0.7224812603522411,0,0,2
162,Fluoropyrimidine Activity WP1601,0.28440828311405736,2.0303951367781155,2.5529060699427757,"['DPYD', 'TYMP']",0.7224812603522411,0,0,2
163,SARS coronavirus and innate immunity WP4912,0.28440828311405736,2.0303951367781155,2.5529060699427757,"['IFNAR2', 'IKBKE']",0.7224812603522411,0,0,2
164,Insulin signaling in adipocytes (diabetic condition) WP3635,0.28865090543623817,3.551470588235294,4.412834536105186,['TBC1D4'],0.7224812603522411,0,0,1
165,Insulin signaling in adipocytes (normal condition) WP3634,0.28865090543623817,3.551470588235294,4.412834536105186,['TBC1D4'],0.7224812603522411,0,0,1
166,Mammary gland development pathway - Puberty (Stage 2 of 4) WP2814,0.28865090543623817,3.551470588235294,4.412834536105186,['STAT5A'],0.7224812603522411,0,0,1
167,Metastatic brain tumor WP2249,0.28865090543623817,3.551470588235294,4.412834536105186,['E2F3'],0.7224812603522411,0,0,1
168,NAD Biosynthesis II (from tryptophan) WP2485,0.28865090543623817,3.551470588235294,4.412834536105186,['HAAO'],0.7224812603522411,0,0,1
169,Thiamine metabolic pathways WP4297,0.28865090543623817,3.551470588235294,4.412834536105186,['SLC25A19'],0.7224812603522411,0,0,1
170,Pyrimidine metabolism WP4022,0.2947193135783551,1.4223684210526315,1.737752809519849,"['PRIM1', 'DPYD', 'ENPP1', 'POLR2K', 'TYMP']",0.7277959226710831,0,0,5
171,Hepatitis C and Hepatocellular Carcinoma WP3646,0.29774876992946164,1.6403530895334173,1.9872963010447326,"['STAT3', 'HIF1A', 'VEGFA']",0.7277959226710831,0,0,3
172,Host-pathogen interaction of human coronaviruses - interferon induction WP4880,0.29774876992946164,1.6403530895334173,1.9872963010447326,"['IFNAR2', 'OAS1', 'IKBKE']",0.7277959226710831,0,0,3
173,mBDNF and proBDNF regulation of GABA neurotransmission WP4829,0.29774876992946164,1.6403530895334173,1.9872963010447326,"['STAT3', 'GABRG3', 'GABRG1']",0.7277959226710831,0,0,3
174,Insulin Signaling WP481,0.2993770462051264,1.2487271246108638,1.5060291916546955,"['SNAP25', 'PTPN1', 'XBP1', 'TBC1D4', 'ENPP1', 'MAP3K8', 'PRKCQ', 'STX4', 'SH2B2', 'MAP2K6']",0.7277959226710831,0,0,10
175,NRF2-ARE regulation WP4357,0.30939944621496235,1.8948172394980907,2.2228520373105507,"['CEBPB', 'HMOX1']",0.7478626614224518,0,0,2
176,Pathogenic Escherichia coli infection WP2272,0.31343260764781283,1.4582964927792514,1.691873168565061,"['TUBB3', 'HCLS1', 'LY96', 'TLR5']",0.750899875509597,0,0,4
177,CAMKK2  Pathway WP4874,0.3161980933279953,1.5794171220400728,1.8185193692587824,"['HDAC4', 'CHRM3', 'HMOX1']",0.750899875509597,0,0,3
178,Calcium Regulation in the Cardiac Cell WP536,0.3169108684508536,1.2647199265381084,1.4533335745130938,"['RGS4', 'CHRM3', 'RYR2', 'GNG3', 'CACNA1A', 'PRKCQ', 'CACNA1C', 'ADRB2']",0.750899875509597,0,0,8
179,Interferon type I signaling pathways WP585,0.3286752007287229,1.4216748768472907,1.5818766624633573,"['IFNAR2', 'STAT5A', 'STAT3', 'MAP2K6']",0.750899875509597,0,0,4
180,Modulators of TCR signaling and T cell activation WP5072,0.3286752007287229,1.4216748768472907,1.5818766624633573,"['TNFAIP3', 'RHOH', 'MAP3K8', 'PRKCQ']",0.750899875509597,0,0,4
181,Purinergic signaling WP4900,0.3342069203738246,1.7761865793780687,1.9466915314740012,"['P2RY12', 'P2RY13']",0.750899875509597,0,0,2
182,Wnt signaling pathway and pluripotency WP399,0.3342934054345665,1.3413915094339623,1.469811251678247,"['WNT5B', 'RACGAP1', 'LRRK2', 'PRKCQ', 'PPARD']",0.750899875509597,0,0,5
183,Host-pathogen interaction of human coronaviruses - MAPK signaling WP4877,0.3346660177400131,1.5228337236533958,1.6669276106028392,"['BST2', 'IFITM2', 'MAP2K6']",0.750899875509597,0,0,3
184,Caloric restriction and aging WP4191,0.3355084550149263,2.8408496732026145,3.1025150004947504,['IGF1'],0.750899875509597,0,0,1
185,Cell Differentiation - Index WP2029,0.3355084550149263,2.8408496732026145,3.1025150004947504,['STAT3'],0.750899875509597,0,0,1
186,Glial Cell Differentiation WP2276,0.3355084550149263,2.8408496732026145,3.1025150004947504,['GAP43'],0.750899875509597,0,0,1
187,Major receptors targeted by epinephrine and norepinephrine WP4589,0.3355084550149263,2.8408496732026145,3.1025150004947504,['ADRB2'],0.750899875509597,0,0,1
188,Nanomaterial-induced inflammasome activation WP3890,0.3355084550149263,2.8408496732026145,3.1025150004947504,['CASP1'],0.750899875509597,0,0,1
189,Selective expression of chemokine receptors during T-cell polarization WP4494,0.3355084550149263,2.8408496732026145,3.1025150004947504,['IL4R'],0.750899875509597,0,0,1
190,IL-2 signaling pathway WP49,0.37149009174455966,1.420983606557377,1.4071049820519441,"['STAT5A', 'STAT3', 'JAK3']",0.8019126228681269,0,0,3
191,ncRNAs involved in Wnt signaling in hepatocellular carcinoma WP4336,0.37149009174455966,1.420983606557377,1.4071049820519441,"['WNT5B', 'ROR2', 'EZH2']",0.8019126228681269,0,0,3
192,Activation of NLRP3 Inflammasome by SARS-CoV-2 WP4876,0.3792841318440592,2.367102396514161,2.294833970997269,['CASP1'],0.8019126228681269,0,0,1
193,ApoE and miR-146 in inflammation and atherosclerosis WP3926,0.3792841318440592,2.367102396514161,2.294833970997269,['TLR2'],0.8019126228681269,0,0,1
194,Aspirin and miRNAs WP4707,0.3792841318440592,2.367102396514161,2.294833970997269,['VEGFA'],0.8019126228681269,0,0,1
195,Cytokines and Inflammatory Response WP530,0.3792841318440592,2.367102396514161,2.294833970997269,['IL15'],0.8019126228681269,0,0,1
196,Estrogen Receptor Pathway WP2881,0.3792841318440592,2.367102396514161,2.294833970997269,['STAT3'],0.8019126228681269,0,0,1
197,Ethanol metabolism resulting in production of ROS by CYP2E1 WP4269,0.3792841318440592,2.367102396514161,2.294833970997269,['PRKCQ'],0.8019126228681269,0,0,1
198,LDLRAD4 and what we know about it WP4904,0.3792841318440592,2.367102396514161,2.294833970997269,['PMEPA1'],0.8019126228681269,0,0,1
199,Fatty Acid Biosynthesis WP357,0.3829464534736682,1.5784688125113657,1.515109244438721,"['ACSL1', 'SCD']",0.8019126228681269,0,0,2
200,IL17 signaling pathway WP2112,0.3829464534736682,1.5784688125113657,1.515109244438721,"['CEBPB', 'STAT3']",0.8019126228681269,0,0,2
201,Intracellular trafficking proteins involved in CMT neuropathy WP4856,0.3829464534736682,1.5784688125113657,1.515109244438721,"['HSPB8', 'LITAF']",0.8019126228681269,0,0,2
202,Type II interferon signaling (IFNG) WP619,0.3829464534736682,1.5784688125113657,1.515109244438721,"['OAS1', 'PSMB9']",0.8019126228681269,0,0,2
203,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,0.387635637098279,1.2466816712834718,1.1814670801173288,"['STAT3', 'NRG1', 'IGF1', 'FGF2', 'VEGFA']",0.8077333718845912,0,0,5
204,G1 to S cell cycle control WP45,0.3897696732135762,1.3749867794817556,1.2955115753950812,"['PRIM1', 'MCM5', 'E2F3']",0.807892168950822,0,0,3
205,Metapathway biotransformation Phase I and II WP702,0.4050110986799212,1.262981207808794,1.141533955484969,"['CYP51A1', 'FMO4', 'SULT4A1', 'GAL3ST4']",0.807892168950822,0,0,4
206,DNA Replication WP466,0.4067447181144631,1.4952192264622275,1.3450536396745023,"['PRIM1', 'MCM5']",0.807892168950822,0,0,2
207,Sphingolipid pathway WP1422,0.4067447181144631,1.4952192264622275,1.3450536396745023,"['UGCG', 'B4GALT6']",0.807892168950822,0,0,2
208,Copper homeostasis WP3286,0.4079146504280687,1.3318647540983606,1.1942795510588884,"['STEAP3', 'SCO2', 'XAF1']",0.807892168950822,0,0,3
209,Retinoblastoma gene in cancer WP2446,0.42014369653684924,1.2353823088455773,1.0712722594975876,"['PRIM1', 'HMGB2', 'E2F3', 'SAP30']",0.807892168950822,0,0,4
210,Alanine and aspartate metabolism WP106,0.4201803242770233,2.0287114845938374,1.7590375373996665,['GAD2'],0.807892168950822,0,0,1
211,BMP Signaling Pathway in Eyelid Development WP3927,0.4201803242770233,2.0287114845938374,1.7590375373996665,['NOTCH1'],0.807892168950822,0,0,1
212,Fatty acid transporters WP5061,0.4201803242770233,2.0287114845938374,1.7590375373996665,['ACSL1'],0.807892168950822,0,0,1
213,Hijack of ubiquitination by SARS-CoV-2 WP4860,0.4201803242770233,2.0287114845938374,1.7590375373996665,['ELOC'],0.807892168950822,0,0,1
214,Hypertrophy Model WP516,0.4201803242770233,2.0287114845938374,1.7590375373996665,['VEGFA'],0.807892168950822,0,0,1
215,ID signaling pathway WP53,0.4201803242770233,2.0287114845938374,1.7590375373996665,['ID2'],0.807892168950822,0,0,1
216,Leptin and adiponectin WP3934,0.4201803242770233,2.0287114845938374,1.7590375373996665,['CPT1A'],0.807892168950822,0,0,1
217,Nanoparticle triggered regulated necrosis WP2513,0.4201803242770233,2.0287114845938374,1.7590375373996665,['FTL'],0.807892168950822,0,0,1
218,Purine metabolism WP4792,0.4201803242770233,2.0287114845938374,1.7590375373996665,['IMPDH1'],0.807892168950822,0,0,1
219,RalA downstream regulated genes WP2290,0.4201803242770233,2.0287114845938374,1.7590375373996665,['YBX3'],0.807892168950822,0,0,1
220,TFs regulate miRNAs related to cardiac hypertrophy WP1559,0.4201803242770233,2.0287114845938374,1.7590375373996665,['STAT3'],0.807892168950822,0,0,1
221,IL-5 signaling pathway WP127,0.4258937721674985,1.2913561847988078,1.1022568614621155,"['STAT5A', 'STAT3', 'CSF2RB']",0.8151722426554384,0,0,3
222,ATM Signaling Network in Development and Disease  WP3878,0.44367847870783517,1.2532304725168757,1.018444167456829,"['HDAC4', 'KAT5', 'CHEK2']",0.8302370660249376,0,0,3
223,Apoptosis WP254,0.4501124973068608,1.1836343732895458,0.944845292050679,"['CASP4', 'CASP1', 'IGF1', 'TNFRSF1B']",0.8302370660249376,0,0,4
224,Bladder cancer WP2828,0.4529371390981536,1.3525056503779909,1.0711870839687605,"['TYMP', 'VEGFA']",0.8302370660249376,0,0,2
225,Gastrin signaling pathway WP4659,0.45620316375543596,1.121390791641377,0.8800865952049819,"['KAT5', 'PXN', 'STAT3', 'PRKCQ', 'RHOB', 'VEGFA']",0.8302370660249376,0,0,6
226,Chemokine signaling pathway WP3929,0.4578036080438704,1.1048038137147047,0.8631997809164523,"['CX3CR1', 'GNG10', 'GNG3', 'CXCL12', 'PXN', 'STAT3', 'JAK3']",0.8302370660249376,0,0,7
227,Cell-type Dependent Selectivity of CCK2R Signaling WP3679,0.4583861499380055,1.7749183006535947,1.3845131780996185,['RYR2'],0.8302370660249376,0,0,1
228,Galanin receptor pathway WP4970,0.4583861499380055,1.7749183006535947,1.3845131780996185,['VEGFA'],0.8302370660249376,0,0,1
229,Leptin Insulin Overlap WP3935,0.4583861499380055,1.7749183006535947,1.3845131780996185,['STAT3'],0.8302370660249376,0,0,1
230,LTF danger signal response pathway WP4478,0.4583861499380055,1.7749183006535947,1.3845131780996185,['TLR2'],0.8302370660249376,0,0,1
231,MFAP5-mediated ovarian cancer cell motility and invasiveness WP3301,0.4583861499380055,1.7749183006535947,1.3845131780996185,['PRKCQ'],0.8302370660249376,0,0,1
232,Overview of nanoparticle effects WP3287,0.4583861499380055,1.7749183006535947,1.3845131780996185,['HMOX1'],0.8302370660249376,0,0,1
233,Tryptophan catabolism leading to NAD+ production WP4210,0.4583861499380055,1.7749183006535947,1.3845131780996185,['HAAO'],0.8302370660249376,0,0,1
234,Exercise-induced Circadian Regulation WP410,0.4612428144582987,1.2172833723653396,0.941971198072535,"['CEBPB', 'TUBB3', 'ERC2']",0.8302370660249376,0,0,3
235,Genotoxicity pathway WP4286,0.4612428144582987,1.2172833723653396,0.941971198072535,"['ITPKC', 'ID2', 'PCDH8']",0.8302370660249376,0,0,3
236,Non-small cell lung cancer WP4255,0.4649133864791872,1.159344525987735,0.8879467911310279,"['STAT5A', 'STAT3', 'E2F3', 'JAK3']",0.8332981461046448,0,0,4
237,Vitamin D-sensitive calcium signaling in depression WP4698,0.47525205005359417,1.2908793334325248,0.9602980242680137,"['ATP2B4', 'CACNA1C']",0.8419551541017217,0,0,2
238,Selenium Micronutrient Network WP15,0.4785633323616307,1.1833333333333333,0.872077286297453,"['PRDX5', 'PLAT', 'ALOX15B']",0.8419551541017217,0,0,3
239,MAPK Signaling Pathway WP382,0.48618409087113046,1.0483957278869094,0.7560693863397013,"['DUSP10', 'LRRK2', 'HSPA6', 'CACNA2D3', 'CACNA1A', 'MAP3K8', 'CACNA1C', 'FGF2', 'HSPA1B', 'HSPA1A', 'MAP2K6']",0.8419551541017217,0,0,11
240,Kynurenine Pathway and links to Cellular Senescence WP5044,0.49407832481863384,1.577523602033406,1.112250718737884,['HAAO'],0.8419551541017217,0,0,1
241,MAPK and NFkB signaling pathways inhibited by Yersinia YopJ WP3849,0.49407832481863384,1.577523602033406,1.112250718737884,['MAP2K6'],0.8419551541017217,0,0,1
242,"NAD metabolism, sirtuins and aging WP3630",0.49407832481863384,1.577523602033406,1.112250718737884,['HIF1A'],0.8419551541017217,0,0,1
243,Omega-3/Omega-6 FA synthesis WP4723,0.49407832481863384,1.577523602033406,1.112250718737884,['ACSL1'],0.8419551541017217,0,0,1
244,Osteopontin Signaling WP1434,0.49407832481863384,1.577523602033406,1.112250718737884,['SPP1'],0.8419551541017217,0,0,1
245,Ovarian infertility WP34,0.49407832481863384,1.577523602033406,1.112250718737884,['CEBPB'],0.8419551541017217,0,0,1
246,Urea cycle and associated pathways WP4595,0.49407832481863384,1.577523602033406,1.112250718737884,['OAT'],0.8419551541017217,0,0,1
247,Cytosolic DNA-sensing pathway WP4655,0.4956189914215809,1.1512184315463003,0.8080952567423466,"['CASP1', 'IKBKE', 'POLR2K']",0.8419551541017217,0,0,3
248,LncRNA involvement in canonical Wnt signaling and colorectal cancer WP4258,0.4956189914215809,1.1512184315463003,0.8080952567423466,"['WNT5B', 'ROR2', 'EZH2']",0.8419551541017217,0,0,3
249,RAC1/PAK1/p38/MMP2 Pathway WP3303,0.4956189914215809,1.1512184315463003,0.8080952567423466,"['STAT5A', 'PXN', 'STAT3']",0.8419551541017217,0,0,3
250,7q11.23 copy number variation syndrome WP4932,0.5053520289668298,1.0755582137161084,0.7340684867725996,"['GRIP1', 'SNAP25', 'BCL7B', 'ATP5MC3', 'NRG1']",0.8466561587780781,0,0,5
251,Androgen receptor signaling pathway WP138,0.5053520289668298,1.0755582137161084,0.7340684867725996,"['KAT5', 'LIMK2', 'STAT3', 'DSTN', 'RHOB']",0.8466561587780781,0,0,5
252,G Protein Signaling Pathways WP35,0.5053520289668298,1.0755582137161084,0.7340684867725996,"['GNG10', 'GNG3', 'PDE4D', 'PDE4B', 'PRKCQ']",0.8466561587780781,0,0,5
253,Apoptosis Modulation and Signaling WP1772,0.5083940055074039,1.0920803334596438,0.738790740920235,"['CASP4', 'CASP1', 'TNFRSF1B', 'HSPA1A']",0.8466561587780781,0,0,4
254,ESC Pluripotency Pathways WP3931,0.5083940055074039,1.0920803334596438,0.738790740920235,"['WNT5B', 'STAT3', 'FGF2', 'MAP2K6']",0.8466561587780781,0,0,4
255,Nucleotide-binding Oligomerization Domain (NOD) pathway WP1433,0.5181738283844164,1.1830332787779596,0.7777787425421797,"['CASP1', 'NLRP1']",0.8528697642280472,0,0,2
256,Oxidative Damage WP3941,0.5181738283844164,1.1830332787779596,0.7777787425421797,"['C5', 'TNFRSF1B']",0.8528697642280472,0,0,2
257,PDGFR-beta pathway WP3972,0.5181738283844164,1.1830332787779596,0.7777787425421797,"['STAT5A', 'STAT3']",0.8528697642280472,0,0,2
258,Cancer immunotherapy by PD-1 blockade WP4585,0.5274219752207625,1.419607843137255,0.9082002771065107,['STAT3'],0.8529808691218171,0,0,1
259,Globo Sphingolipid Metabolism WP1424,0.5274219752207625,1.419607843137255,0.9082002771065107,['ST6GALNAC5'],0.8529808691218171,0,0,1
260,Metabolism of Spingolipids in ER and Golgi apparatus WP4142,0.5274219752207625,1.419607843137255,0.9082002771065107,['UGCG'],0.8529808691218171,0,0,1
261,SREBF and miR33 in cholesterol and lipid homeostasis WP2011,0.5274219752207625,1.419607843137255,0.9082002771065107,['SCD'],0.8529808691218171,0,0,1
262,RANKL/RANK signaling pathway WP2018,0.5288629510299171,1.0919293820933165,0.6955873546534116,"['CALCR', 'TNFRSF11A', 'MAP2K6']",0.8529808691218171,0,0,3
263,Breast cancer pathway WP4262,0.5303889651659979,1.0436822755417956,0.661845526185888,"['NOTCH1', 'WNT5B', 'E2F3', 'IGF1', 'FGF2']",0.8529808691218171,0,0,5
264,Prolactin Signaling Pathway WP2037,0.5364782492711437,1.0513896490907986,0.6547310977633858,"['STAT5A', 'PTPN1', 'PXN', 'STAT3']",0.8529808691218171,0,0,4
265,Prion disease pathway WP3995,0.538740454031877,1.135581014729951,0.7023811095958747,"['HSPA5', 'STAT3']",0.8529808691218171,0,0,2
266,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.5450202176160398,1.0645081967213115,0.6460845023753161,"['STAT5A', 'PFN1', 'PFN2']",0.8529808691218171,0,0,3
267,IL-3 signaling pathway WP286,0.5450202176160398,1.0645081967213115,0.6460845023753161,"['STAT5A', 'STAT3', 'CSF2RB']",0.8529808691218171,0,0,3
268,"Non-genomic actions of 1,25 dihydroxyvitamin D3 WP4341",0.5450202176160398,1.0645081967213115,0.6460845023753161,"['PRKCQ', 'IFI44L', 'TLR2']",0.8529808691218171,0,0,3
269,Hepatitis B infection WP4666,0.5529072449295935,1.0033169983665033,0.5945305594268009,"['STAT5A', 'TICAM2', 'STAT3', 'IKBKE', 'JAK3', 'MAP2K6', 'TLR2']",0.8529808691218171,0,0,7
270,Airway smooth muscle cell contraction WP4962,0.5585713965644051,1.2904040404040404,0.7514962558983947,['ADRB2'],0.8529808691218171,0,0,1
271,Cholesterol Biosynthesis Pathway WP197,0.5585713965644051,1.2904040404040404,0.7514962558983947,['CYP51A1'],0.8529808691218171,0,0,1
272,Eicosanoid metabolism via cyclooxygenases (COX) WP4719,0.5585713965644051,1.2904040404040404,0.7514962558983947,['PPARD'],0.8529808691218171,0,0,1
273,Kallmann's Syndrome WP5074,0.5585713965644051,1.2904040404040404,0.7514962558983947,['PRKCQ'],0.8529808691218171,0,0,1
274,Oxidation by Cytochrome P450 WP43,0.5585713965644051,1.2904040404040404,0.7514962558983947,['CYP51A1'],0.8529808691218171,0,0,1
275,Pathways of nucleic acid metabolism and innate immune sensing WP4705,0.5585713965644051,1.2904040404040404,0.7514962558983947,['OAS1'],0.8529808691218171,0,0,1
276,Type II diabetes mellitus WP1584,0.5585713965644051,1.2904040404040404,0.7514962558983947,['CACNA1A'],0.8529808691218171,0,0,1
277,Vitamin B12 metabolism WP1533,0.5585713965644051,1.2904040404040404,0.7514962558983947,['PLAT'],0.8529808691218171,0,0,1
278,Notch Signaling WP268,0.5780216632931011,1.0512214342001576,0.5762206495738283,"['NOTCH1', 'RBPJ']",0.8766059153592402,0,0,2
279,PI3K/AKT/mTOR - VitD3 signaling WP4141,0.5876707627651835,1.1827342047930283,0.6287278014949563,['LDHA'],0.8766059153592402,0,0,1
280,Sleep regulation WP3591,0.5876707627651835,1.1827342047930283,0.6287278014949563,['PER3'],0.8766059153592402,0,0,1
281,Wnt signaling in kidney disease WP4150,0.5876707627651835,1.1827342047930283,0.6287278014949563,['WNT5B'],0.8766059153592402,0,0,1
282,Regulation of Actin Cytoskeleton WP51,0.6018158282195607,0.9561483072024878,0.485535756832035,"['CHRM3', 'PXN', 'IQGAP1', 'PFN1', 'SSH2', 'FGF2']",0.8766059153592402,0,0,6
283,Myometrial relaxation and contraction pathways WP289,0.6121421897333952,0.9454146073585942,0.46400068491952967,"['RGS4', 'RYR2', 'GNG3', 'PDE4D', 'PDE4B', 'PRKCQ']",0.8766059153592402,0,0,6
284,Amyotrophic lateral sclerosis (ALS) WP2447,0.6147962381368965,0.9784976578813703,0.476004262516754,"['CASP1', 'MAP2K6']",0.8766059153592402,0,0,2
285,Integrated Cancer Pathway WP1971,0.6147962381368965,0.9784976578813703,0.476004262516754,"['CHEK2', 'BACH1']",0.8766059153592402,0,0,2
286,Metabolic reprogramming in colon cancer WP4290,0.6147962381368965,0.9784976578813703,0.476004262516754,"['LDHA', 'PGAM1']",0.8766059153592402,0,0,2
287,Phosphodiesterases in neuronal function WP4222,0.6147962381368965,0.9784976578813703,0.476004262516754,"['PDE4D', 'PDE4B']",0.8766059153592402,0,0,2
288,TGF-beta Receptor Signaling WP560,0.6147962381368965,0.9784976578813703,0.476004262516754,"['STAT3', 'SPP1']",0.8766059153592402,0,0,2
289,Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway WP2203,0.6147962381368965,0.9784976578813703,0.476004262516754,"['STAT5A', 'STAT3']",0.8766059153592402,0,0,2
290,"4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression WP3879",0.6148547891090159,1.091628959276018,0.5309346537598779,['MAP2K6'],0.8766059153592402,0,0,1
291,Apoptosis Modulation by HSP70 WP384,0.6148547891090159,1.091628959276018,0.5309346537598779,['HSPA1A'],0.8766059153592402,0,0,1
292,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells WP4301,0.6148547891090159,1.091628959276018,0.5309346537598779,['RAB27A'],0.8766059153592402,0,0,1
293,Monoamine Transport WP727,0.6148547891090159,1.091628959276018,0.5309346537598779,['NECTIN2'],0.8766059153592402,0,0,1
294,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling WP3612,0.6148547891090159,1.091628959276018,0.5309346537598779,['HMOX1'],0.8766059153592402,0,0,1
295,Purine metabolism and related disorders WP4224,0.6148547891090159,1.091628959276018,0.5309346537598779,['IMPDH1'],0.8766059153592402,0,0,1
296,Triacylglyceride synthesis WP325,0.6148547891090159,1.091628959276018,0.5309346537598779,['LIPC'],0.8766059153592402,0,0,1
297,T-cell receptor (TCR) signaling pathway WP69,0.6154892597203175,0.9455938697318008,0.4589324325360922,"['CD83', 'MAP3K8', 'PRKCQ', 'OPRM1']",0.8766059153592402,0,0,4
298,AGE/RAGE pathway WP2324,0.6207112534184002,0.9456830601092896,0.4509861094085951,"['STAT5A', 'STAT3', 'HIF1A']",0.8810767120670578,0,0,3
299,SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039,0.632241978218737,0.945771958537916,0.43362044164937075,"['IFNAR2', 'CXCL12']",0.8850505747779418,0,0,2
300,Signaling of Hepatocyte Growth Factor Receptor WP313,0.632241978218737,0.945771958537916,0.43362044164937075,"['PXN', 'STAT3']",0.8850505747779418,0,0,2
301,B Cell Receptor Signaling Pathway WP23,0.6350797818947649,0.9207322282980178,0.4180167104763486,"['BCL6', 'HCLS1', 'E2F3', 'PIK3AP1', 'MAP2K6']",0.8850505747779418,0,0,5
302,Cell migration and invasion through p75NTR WP4561,0.6402493519670217,1.0135387488328664,0.4519344612112313,['STAT3'],0.8850505747779418,0,0,1
303,Overview of interferons-mediated signaling pathway WP4558,0.6402493519670217,1.0135387488328664,0.4519344612112313,['IFNAR2'],0.8850505747779418,0,0,1
304,Photodynamic therapy-induced NF-kB survival signaling WP3617,0.6402493519670217,1.0135387488328664,0.4519344612112313,['VEGFA'],0.8850505747779418,0,0,1
305,Signal Transduction of S1P Receptor WP26,0.6402493519670217,1.0135387488328664,0.4519344612112313,['RACGAP1'],0.8850505747779418,0,0,1
306,Sphingolipid Metabolism (general overview) WP4725,0.6402493519670217,1.0135387488328664,0.4519344612112313,['UGCG'],0.8850505747779418,0,0,1
307,Kit receptor signaling pathway WP304,0.6484787354104151,0.9052319497732821,0.39207955339179235,"['STAT5A', 'STAT3', 'SH2B2']",0.8906055359694987,0,0,3
308,Pathways affected in adenoid cystic carcinoma WP3651,0.6484787354104151,0.9052319497732821,0.39207955339179235,"['CEBPA', 'NOTCH1', 'CHEK2']",0.8906055359694987,0,0,3
309,Nucleotide metabolism WP404,0.663972067715889,0.9458605664488018,0.38734427628276324,['IMPDH1'],0.9060005956252292,0,0,1
310,Sphingolipid Metabolism (integrated pathway) WP4726,0.663972067715889,0.9458605664488018,0.38734427628276324,['UGCG'],0.9060005956252292,0,0,1
311,G13 Signaling Pathway WP524,0.6808679025559263,0.8594951148142638,0.3303787206245445,"['IQGAP1', 'PFN1']",0.9172056297564289,0,0,2
312,TGF-beta receptor signaling in skeletal dysplasias WP4816,0.6808679025559263,0.8594951148142638,0.3303787206245445,"['STAT3', 'SPP1']",0.9172056297564289,0,0,2
313,Nuclear receptors WP170,0.6861328338962088,0.8866421568627451,0.3339839448792791,['PPARD'],0.9172056297564289,0,0,1
314,Tryptophan metabolism WP465,0.6861328338962088,0.8866421568627451,0.3339839448792791,['HAAO'],0.9172056297564289,0,0,1
315,Vitamin D in inflammatory diseases WP4482,0.6861328338962088,0.8866421568627451,0.3339839448792791,['MAP2K6'],0.9172056297564289,0,0,1
316,Amino Acid metabolism WP3925,0.687362138611792,0.8506229508196721,0.318893436445805,"['ARG2', 'LDHA', 'OAT']",0.9172056297564289,0,0,3
317,Thyroid stimulating hormone (TSH) signaling pathway WP2032,0.687362138611792,0.8506229508196721,0.318893436445805,"['PDE4D', 'STAT3', 'MAP2K6']",0.9172056297564289,0,0,3
318,miRNA regulation of p53 pathway in prostate cancer WP3982,0.7068343351912516,0.8343906189926951,0.28949930252374173,['CHEK2'],0.9372756231532897,0,0,1
319,PKC-gamma calcium signaling pathway in ataxia WP4760,0.7068343351912516,0.8343906189926951,0.28949930252374173,['CACNA1A'],0.9372756231532897,0,0,1
320,NAD Metabolism in Oncogene-Induced Senescence and Mitochondrial Dysfunction-Associated Senescence WP5046,0.7261725159646142,0.7879448075526507,0.2521168618684172,['SCO2'],0.9539471250094156,0,0,1
321,Nanoparticle triggered autophagic cell death WP2509,0.7261725159646142,0.7879448075526507,0.2521168618684172,['VMP1'],0.9539471250094156,0,0,1
322,Oxidative Stress WP408,0.7261725159646142,0.7879448075526507,0.2521168618684172,['HMOX1'],0.9539471250094156,0,0,1
323,VEGFA-VEGFR2 Signaling Pathway WP3888,0.7347575137569424,0.8802064359441408,0.27129260436588004,"['HDAC4', 'PTPN1', 'STAT3', 'PXN', 'IQGAP1', 'ADRB2', 'LDB2', 'PTPN14', 'APOLD1', 'VEGFA', 'INPP4B', 'SDCBP', 'LDHA', 'TXNIP', 'ELOC', 'PFN1', 'CLIC1', 'HSPA1A', 'MAP2K6']",0.9539765462731508,0,0,19
324,T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection WP3863,0.7373852085592647,0.7662228513292343,0.23342584736744793,"['MAP3K8', 'PRKCQ']",0.9539765462731508,0,0,2
325,Alpha 6 Beta 4 signaling pathway WP244,0.744237021915224,0.7463880288957688,0.2204798269865948,['LAMA2'],0.9539765462731508,0,0,1
326,Ethanol effects on histone modifications WP3996,0.744237021915224,0.7463880288957688,0.2204798269865948,['HDAC4'],0.9539765462731508,0,0,1
327,Folate Metabolism WP176,0.744237021915224,0.7463880288957688,0.2204798269865948,['PLAT'],0.9539765462731508,0,0,1
328,Nanoparticle-mediated activation of receptor signaling WP2643,0.744237021915224,0.7463880288957688,0.2204798269865948,['PXN'],0.9539765462731508,0,0,1
329,Nephrotic syndrome WP4758,0.744237021915224,0.7463880288957688,0.2204798269865948,['E2F3'],0.9539765462731508,0,0,1
330,Physiological and pathological hypertrophy of the heart WP1528,0.744237021915224,0.7463880288957688,0.2204798269865948,['STAT3'],0.9539765462731508,0,0,1
331,Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865,0.7501097298763412,0.7459729520199845,0.21449391212026123,"['CXCL12', 'IKBKE']",0.9585994433162909,0,0,2
332,Pathways Regulating Hippo Signaling WP4540,0.7552728289095448,0.7589578454332553,0.21302142846608585,"['CDH12', 'PRKCQ', 'CDH18']",0.9596817722148057,0,0,3
333,TLR4 Signaling and Tolerance WP3851,0.7611116133215569,0.7089869281045752,0.1935358947395262,['IKBKE'],0.9596817722148057,0,0,1
334,DNA IR-double strand breaks and cellular response via ATM WP3959,0.7623004148089236,0.726761509085568,0.19725365218543434,"['KAT5', 'CHEK2']",0.9596817722148057,0,0,2
335,p53 transcriptional gene network WP4963,0.7623004148089236,0.726761509085568,0.19725365218543434,"['NOTCH1', 'DRAM1']",0.9596817722148057,0,0,2
336,Translation inhibitors in chronically activated PDGFRA cells WP4566,0.7623004148089236,0.726761509085568,0.19725365218543434,"['PIM1', 'MAP2K6']",0.9596817722148057,0,0,2
337,Glycerophospholipid Biosynthetic Pathway WP2533,0.7768745502497187,0.6751478369125428,0.1704588923875878,['PGS1'],0.9665233375165618,0,0,1
338,Melatonin metabolism and effects WP3298,0.7768745502497187,0.6751478369125428,0.1704588923875878,['PER3'],0.9665233375165618,0,0,1
339,SARS-CoV-2 mitochondrial interactions WP5038,0.7768745502497187,0.6751478369125428,0.1704588923875878,['IKBKE'],0.9665233375165618,0,0,1
340,Signal transduction through IL1R WP4496,0.7768745502497187,0.6751478369125428,0.1704588923875878,['MAP2K6'],0.9665233375165618,0,0,1
341,Hippo-Merlin Signaling Dysregulation WP4541,0.7845016564087993,0.7201166990830786,0.17477707231903508,"['ITGAX', 'CDH12', 'CDH18']",0.9677965323271229,0,0,3
342,Integrin-mediated Cell Adhesion WP185,0.7845016564087993,0.7201166990830786,0.17477707231903508,"['PXN', 'ITGAX', 'MAP2K6']",0.9677965323271229,0,0,3
343,Structural Pathway of Interleukin 1 (IL-1) WP2637,0.7851406472102361,0.6911500538900642,0.16718395139692466,"['MAP3K8', 'MAP2K6']",0.9677965323271229,0,0,2
344,Overview of leukocyte-intrinsic Hippo pathway functions WP4542,0.7915989538296178,0.6443850267379679,0.15059303002531774,['VMP1'],0.9677965323271229,0,0,1
345,Regucalcin in proximal tubule epithelial kidney cells WP4838,0.7915989538296178,0.6443850267379679,0.15059303002531774,['PRKCQ'],0.9677965323271229,0,0,1
346,Glioblastoma signaling pathways WP2261,0.7935810885395344,0.7080327868852458,0.16369686402180902,"['SPRY2', 'PRKCQ', 'MAP2K6']",0.9677965323271229,0,0,3
347,Endometrial cancer WP4155,0.7958211213483068,0.6746161639778661,0.15406940641985065,"['CTNNA3', 'FGF2']",0.9677965323271229,0,0,2
348,Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.8042249264083908,0.7509731597439897,0.1636192457198693,"['STAT5A', 'GRIP1', 'STAT3', 'SPP1', 'YBX1', 'SH2B2']",0.9677965323271229,0,0,6
349,One-carbon metabolism and related pathways WP3940,0.8053531427403009,0.6162972435350952,0.13341258287191785,['GAD2'],0.9677965323271229,0,0,1
350,Parkinson's disease pathway WP2371,0.8053531427403009,0.6162972435350952,0.13341258287191785,['LRRK2'],0.9677965323271229,0,0,1
351,Renin-angiotensin-aldosterone system (RAAS) WP4756,0.8053531427403009,0.6162972435350952,0.13341258287191785,['CAMK1G'],0.9677965323271229,0,0,1
352,Tumor suppressor activity of SMARCB1 WP4204,0.8053531427403009,0.6162972435350952,0.13341258287191785,['EZH2'],0.9677965323271229,0,0,1
353,Pancreatic adenocarcinoma pathway WP4263,0.8107844052505782,0.6850343733474352,0.14368808229957655,"['STAT3', 'E2F3', 'VEGFA']",0.9715631824957353,0,0,3
354,Small cell lung cancer WP4658,0.8157812640621918,0.6438030055051331,0.13108409818669658,"['LAMA2', 'E2F3']",0.9738690917301828,0,0,2
355,Senescence and Autophagy in Cancer WP615,0.8189223839131158,0.6740827478532396,0.13465879328197816,"['CEBPB', 'PLAT', 'IGF1']",0.9738690917301828,0,0,3
356,ATM Signaling Pathway WP2516,0.8302020084907127,0.5668627450980392,0.10548534780734672,['CHEK2'],0.9738690917301828,0,0,1
357,Kisspeptin/kisspeptin receptor system in the ovary WP4871,0.8302020084907127,0.5668627450980392,0.10548534780734672,['PRKCQ'],0.9738690917301828,0,0,1
358,Neural Crest Cell Migration during Development WP4564,0.8302020084907127,0.5668627450980392,0.10548534780734672,['STAT3'],0.9738690917301828,0,0,1
359,MAPK Cascade WP422,0.8414120436712499,0.5449974861739567,0.09410678370210214,['MAP2K6'],0.9738690917301828,0,0,1
360,Integrated breast cancer pathway WP1984,0.8417499221903113,0.693046955624355,0.11939280232565312,"['ITPKC', 'CHEK2', 'MAP3K7CL', 'BACH1', 'VEGFA']",0.9738690917301828,0,0,5
361,MET in type 1 papillary renal cell carcinoma WP4205,0.8424551254090572,0.6025002611693422,0.10328956104815691,"['STAT3', 'JAK3']",0.9738690917301828,0,0,2
362,Focal Adhesion WP306,0.8474874075586168,0.6862385028104241,0.11355826582630349,"['LAMA2', 'PXN', 'SPP1', 'IGF1', 'VEGFA']",0.9738690917301828,0,0,5
363,Cell cycle WP179,0.8485548815580899,0.6335453878150232,0.10404115031790374,"['CHEK2', 'MCM5', 'E2F3']",0.9738690917301828,0,0,3
364,22q11.2 copy number variation syndrome WP4657,0.8505374574945413,0.5898799781778505,0.09549379761366941,"['OAT', 'EMC10']",0.9738690917301828,0,0,2
365,Joubert Syndrome WP4656,0.8505374574945413,0.5898799781778505,0.09549379761366941,"['KAT5', 'KIAA0586']",0.9738690917301828,0,0,2
366,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling WP3850,0.8518831129695388,0.5247518760590656,0.08412084953543661,['IGF1'],0.9738690917301828,0,0,1
367,Mitochondrial CIV Assembly WP4922,0.8518831129695388,0.5247518760590656,0.08412084953543661,['SCO2'],0.9738690917301828,0,0,1
368,NO/cGMP/PKG mediated Neuroprotection WP4008,0.8518831129695388,0.5247518760590656,0.08412084953543661,['TSPO'],0.9738690917301828,0,0,1
369,p38 MAPK Signaling Pathway WP400,0.8518831129695388,0.5247518760590656,0.08412084953543661,['MAP2K6'],0.9738690917301828,0,0,1
370,Thermogenesis WP4321,0.8552709332251325,0.6241562198649951,0.09757869801031907,"['CPT1A', 'ACSL1', 'MGLL']",0.9738690917301828,0,0,3
371,Aryl Hydrocarbon Receptor Netpath WP2586,0.861663854429272,0.5059523809523809,0.07533127248021797,['VEGFA'],0.9738690917301828,0,0,1
372,Disruption of postsynaptic signaling by CNV WP4875,0.861663854429272,0.5059523809523809,0.07533127248021797,['RYR2'],0.9738690917301828,0,0,1
373,Neural Crest Cell Migration in Cancer WP4565,0.861663854429272,0.5059523809523809,0.07533127248021797,['STAT3'],0.9738690917301828,0,0,1
374,Target Of Rapamycin (TOR) Signaling WP1471,0.861663854429272,0.5059523809523809,0.07533127248021797,['PRR5'],0.9738690917301828,0,0,1
375,Ebola Virus Pathway on Host WP4217,0.8694803283391476,0.6353388313868747,0.08885821547649654,"['BST2', 'IQGAP1', 'IKBKE', 'RHOB']",0.9738690917301828,0,0,4
376,EGF/EGFR signaling pathway WP437,0.8700174808105544,0.6779308072487644,0.0943964242771643,"['STAT5A', 'PLSCR1', 'LIMK2', 'STAT3', 'SPRY2', 'IQGAP1']",0.9738690917301828,0,0,6
377,Fas ligand pathway and stress induction of heat shock proteins WP314,0.8707997098549338,0.4884494027496056,0.06757369386564648,['LMNB1'],0.9738690917301828,0,0,1
378,Initiation of transcription and translation elongation at the HIV-1 LTR WP3414,0.8707997098549338,0.4884494027496056,0.06757369386564648,['HDAC4'],0.9738690917301828,0,0,1
379,DNA IR-damage and cellular response via ATR WP4016,0.8725682878622677,0.5549886075543147,0.07565291744400057,"['BCL6', 'CHEK2']",0.9738690917301828,0,0,2
380,Photodynamic therapy-induced AP-1 survival signaling. WP3611,0.8793331344274569,0.4721132897603486,0.060709737486576244,['MAP2K6'],0.9743443569373935,0,0,1
381,Endoderm differentiation WP2853,0.8795958017401118,0.5892076502732241,0.07559109524739394,"['NOTCH1', 'NCAPG2', 'EZH2']",0.9743443569373935,0,0,3
382,Ciliopathies WP4803,0.879904360165684,0.6212309857630055,0.07948157146173608,"['KIAA0586', 'LRRC6', 'DNAAF4', 'CCDC40']",0.9743443569373935,0,0,4
383,Glycogen Synthesis and Degradation WP500,0.8873037923966247,0.45683111954459205,0.0546223198313495,['PYGL'],0.9750447536551462,0,0,1
384,Head and Neck Squamous Cell Carcinoma WP4674,0.8915756098772684,0.5239740558889495,0.06013389997166064,"['NOTCH1', 'VEGFA']",0.9750447536551462,0,0,2
385,Histone Modifications WP2369,0.8947487406994983,0.44250408496732024,0.049211913319396346,['EZH2'],0.9750447536551462,0,0,1
386,Microglia Pathogen Phagocytosis Pathway WP3937,0.8947487406994983,0.44250408496732024,0.049211913319396346,['FCER1G'],0.9750447536551462,0,0,1
387,Wnt signaling WP428,0.8973031228056934,0.5143877399196548,0.055739849948675466,"['WNT5B', 'ROR2']",0.9750447536551462,0,0,2
388,Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.8986027985853201,0.5947973381730187,0.06359226251980549,"['PTPN1', 'SCD', 'MAP3K8', 'MAP2K6']",0.9750447536551462,0,0,4
389,Eukaryotic Transcription Initiation WP405,0.9017025997972774,0.42904535551594375,0.044393548296828886,['POLR2K'],0.9750447536551462,0,0,1
390,Interleukin-11 Signaling Pathway WP2332,0.9017025997972774,0.42904535551594375,0.044393548296828886,['STAT3'],0.9750447536551462,0,0,1
391,Alzheimer's disease WP2059,0.9027479968470303,0.5051437923778349,0.05168218973751751,"['VMP1', 'CACNA1C']",0.9750447536551462,0,0,2
392,IL-6 signaling pathway WP364,0.9081977138064482,0.41637831603229525,0.0400943911350263,['STAT3'],0.9750447536551462,0,0,1
393,Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway WP4577,0.9081977138064482,0.41637831603229525,0.0400943911350263,['FTL'],0.9750447536551462,0,0,1
394,PDGF Pathway WP2526,0.9081977138064482,0.41637831603229525,0.0400943911350263,['STAT3'],0.9750447536551462,0,0,1
395,Sterol regulatory element-binding proteins (SREBP) signaling WP1982,0.9128386939360553,0.48761216772955585,0.04446832359941685,"['SCD', 'CYP51A1']",0.9766005019085561,0,0,2
396,Splicing factor NOVA regulated synaptic proteins WP4148,0.9142642996590739,0.40443510737628385,0.036251775912162394,['EPB41L3'],0.9766005019085561,0,0,1
397,Corticotropin-releasing hormone signaling pathway WP2355,0.9175079649482708,0.47929207467613527,0.04126418047977125,"['PRKCQ', 'TBX19']",0.9769612346511359,0,0,2
398,Primary focal segmental glomerulosclerosis (FSGS) WP2572,0.919930587260389,0.3931554103122731,0.032811594831094006,['NOTCH1'],0.9769612346511359,0,0,1
399,Regulation of Microtubule Cytoskeleton WP2038,0.92522294942664,0.38248542660307366,0.029726975467721215,['STAT3'],0.9769612346511359,0,0,1
400,Synaptic signaling pathways associated with autism spectrum disorder WP4539,0.92522294942664,0.38248542660307366,0.029726975467721215,['CACNA1C'],0.9769612346511359,0,0,1
401,Leptin signaling pathway WP2034,0.9261500120451668,0.46347025837782724,0.03555700135928361,"['PTPN1', 'STAT3']",0.9769612346511359,0,0,2
402,Wnt Signaling Pathway WP363,0.9301660243113792,0.37237702098383213,0.02695718731100172,['ROR2'],0.9787567867754065,0,0,1
403,DNA damage response WP707,0.9347828289607792,0.36278699513993634,0.02446673412381736,['CHEK2'],0.9808324156543207,0,0,1
404,Energy Metabolism WP1541,0.9390948660520091,0.3536764705882353,0.022224596535658826,['PPARD'],0.9808324156543207,0,0,1
405,miRNA regulation of DNA damage response WP1530,0.9390948660520091,0.3536764705882353,0.022224596535658826,['CHEK2'],0.9808324156543207,0,0,1
406,Mesodermal commitment pathway WP2857,0.9441664171239522,0.42811089619600257,0.024596186413652635,"['BHLHE40', 'NCAPG2']",0.9837004789247088,0,0,2
407,ErbB signaling pathway WP673,0.9501311549041583,0.41542312506017137,0.021251072207555725,"['STAT5A', 'NRG1']",0.987482748217344,0,0,2
408,DNA damage response (only ATM dependent) WP710,0.9554851307509556,0.4034603694178162,0.01837200251671342,"['WNT5B', 'BCL6']",0.9876216889286639,0,0,2
409,TGF-beta Signaling Pathway WP366,0.9588681325195276,0.4501569584931985,0.018907365962549175,"['EID2', 'LIMK2', 'MAP2K6']",0.9876216889286639,0,0,3
410,IL-1 signaling pathway WP195,0.9596040523633117,0.3073316283034953,0.012672673727216218,['MAP2K6'],0.9876216889286639,0,0,1
411,Mitochondrial complex I assembly model OXPHOS system WP4324,0.9596040523633117,0.3073316283034953,0.012672673727216218,['TMEM70'],0.9876216889286639,0,0,1
412,AMP-activated protein kinase (AMPK) signaling WP1403,0.9622769136645006,0.300757891809206,0.011565048535885048,['CPT1A'],0.9879687730099121,0,0,1
413,Oxidative phosphorylation WP623,0.9671044994744719,0.2884153661464586,0.009647125900825998,['ATP5MC3'],0.9903530986957401,0,0,1
414,Melanoma WP4685,0.9692817561702987,0.28261437908496734,0.008817551477053532,['E2F3'],0.9903530986957401,0,0,1
415,Male infertility WP4673,0.9766436761453654,0.2615589445654805,0.006181528651144698,['EPSTI1'],0.9954146882951163,0,0,1
416,Proteasome Degradation WP183,0.9796347436818186,0.2521591970121382,0.005188298360771885,['PSMB9'],0.9954146882951163,0,0,1
417,16p11.2 proximal deletion syndrome WP4949,0.9834195991936049,0.23925445884568516,0.004000189604552915,['MAP2K6'],0.9954146882951163,0,0,1
418,Ras signaling WP4223,0.9847592468409594,0.373639924561149,0.005738394518955742,"['GNG10', 'GNG3', 'KSR2']",0.9954146882951163,0,0,3
419,Ciliary landscape WP4352,0.9871003586847832,0.43605957829356,0.005661607523727282,"['DOCK5', 'TBC1D4', 'MCM5', 'IQGAP1', 'CCDC40']",0.9954146882951163,0,0,5
420,Nonalcoholic fatty liver disease WP4396,0.9883550096547253,0.3575993331480967,0.004188676945004323,"['VMP1', 'CEBPA', 'XBP1']",0.9954146882951163,0,0,3
421,Fragile X Syndrome  WP4549,0.9927926624601616,0.27862131548670416,0.0020153894182326224,"['GRIP1', 'CPT1A']",0.9975090171511838,0,0,2
422,Electron Transport Chain (OXPHOS system in mitochondria) WP111,0.9972158497272654,0.16557093425605537,0.0004616172662859036,['ATP5MC3'],0.9994996950865883,0,0,1
423,mRNA Processing WP411,0.9994996950865883,0.12756981580510993,6.383977665923837e-05,['YBX1'],0.9994996950865883,0,0,1
